3Colonno RJ, Genovesi EV, Medina L, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection [ J] . J Infect Dis, 2001,184 (10): 1236.
4Gish RG, LeungNWY, WrightTL, etal. Doserange study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection [ J] . Antimicrob Agents Chemother,2002, 46(6): 1734.
5Das K, Xiong X, Yang H, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) [ J] . J Virol, 2001,75(10):4771.
6Van Bommel F, Schemick A, Hopf U, et al. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation [J] . Gastroenterology, 2003, 124(2):586.
7Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed [J] . J Infect Dis,
8Peek SF, Cote PJ, Jacob JR, et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax) [ J]
9Ying C, De Clercq E, Nicholson W, et al. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir[J]. J Viral Hepat, 2000, 7(2): 161.
10Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection[J]. N Engl J Med, 1995, 333(25): 1657.
二级参考文献8
1Colonno RJ,Genovesi EV,Medina I,et al.Long-term entecavir treatment result in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection J Infect Dis,2001,184:1236-1245.
2Innaimo SF,Seifer M,Bisaeehi GS,et al.Identification of BMS-200475 as potent and selective inhibitor of hepatitis B virus.Antimierob Agents Chemother,1997,41:1444—1448.
3De Man RA,Wolters LMM,Nevens F,et al.Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.Hepatology,2001,34:578—582.
4Levine S,Hernandez D,Yamanaka G,et al.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Amimicrob Agents Chemother,2002,46:2525-2532.
5Wolters LMM,Hansen BE,Niesters HGM,et al.Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B.J Hepatol,2002,37:137-144.
6Lai CL,Rosmawati M,Lao J,et al.Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.Gastroenterology,2002,123:1831—1838.
9Chen CJ,Yang HI,Su J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Journal of the American Medical Association, The . 2006
10Torresi J,Locarnini S.Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology . 2000
